drugset / Trial / NCT01039623

Assessment of Safety and Immunogenicity of Intradermal Unadjuvanted Portion of Pandemrix® Via a Microneedle Device With Intramuscular Adjuvanted Pandemrix® as Reference

NCT01039623

Unknown 200 enrolled Hadassah Medical Organization
RandomizedParallel-groupOpen-labelPrevention

Summary

Healthy volunteers will be vaccinated against H1N1 pandemic influenza. One group will receive the adjuvant vaccine while the other group will get intradermal antigen, without the adjuvant. The antibody production will be compared.

Timeline

Start
2010-01
Primary completion
2011-12
Completion
2012-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Pandemrix Vaccine Other

Indications

No indication recorded.